NSAID API Market Expected to Rise Steadily throughout 2017-2025
A sample of this report is available upon request @ https://www.persistencemarketresearch.com/samples/17038
The term nonsteroidal distinguishes these drugs from steroids, which, among a broad range of other effects, have a similar eicosanoid-depressing, anti-inflammatory action. APIs of good quality is essential for the manufacture of effective and safe medicines. The growing pool of geriatrics is driving the demand for various types of drugs, which in turn is leading to a soaring demand of NSAID API market. However, not all pharmaceutical companies possess in-house API manufacturing capabilities. Furthermore, a single company cannot produce all the APIs required for their formulation offerings.
NSAID API Market: Drivers and Restraints
The improving access to healthcare with the rapid penetration of technology and other developments in the healthcare sector has increased the consumption of drugs, thereby directly creating a positive impact on NSAID API market. Furthermore, growing healthcare budgets of developed and developing countries are also making a significant contribution towards propelling the sale of NSAID API market. Furthermore, the compliance by Indian active pharmaceutical ingredients manufacturers with U.S. FDA norms is also anticipated to result in increasing applications of this substance.
NSAID API Market: Segmentation
The market for NSAID API is segmented by product type, by a manufacturing process, by drug type and regions:
By product type, the NSAID API market can be segmented into,
By manufacturing process, the NSAID API market can be segmented into,
By drug type, the NSAID API market can be segmented into,
Branded Prescription Drugs
Generic Prescription Drugs
The captive API manufacturing segment is witnessing a continuous decline in the global NSAID API market due to the high degree of competition and reduced profitability. High research & development costs and pricing pressure on finished products are important factors due to which pharmaceutical companies prefer outsourcing their API production instead of in-house manufacturing.
NSAID API Market: Overview
The global pharmaceutical industry has suffered enormously due to patent expiry of blockbuster drugs in the past few years. However, this has facilitated a surge in demand for low-cost substitutes across the globe resulting in a boost to NSAID API manufacturing. The approvals of biosimilars in Europe has added to the total NSAID API market revenue. Advancements in the production technology have enabled the production of biosimilars that are not exact copies of innovator drugs, but highly comparable regarding safety and efficacy. Europe has been the frontrunner in approving biosimilars, and the WHO has also set guidelines on similar lines of those set by the European Union. Regulatory pathways in the biosimilars space in different nations are evolving, and this implies a great market opportunity ahead for the biopharmaceutical companies.
NSAID API Market: Region-wise Outlook
Regionally, the market can be segmented into North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa. North America dominated the global NSAID API market due to high demand for APIs in drug formulations and research and development programs in this region. The region is expected to continue its dominance in the coming years owing to increasing preference for generic medicines as a result of high healthcare costs in the U.S. Among other regions, Asia-Pacific is the next largest market for APIs. This region has become the most attractive market due to clustering of a large number of generic medicine manufacturers.
To view TOC of this report is available upon request @ https://www.persistencemarketresearch.com/toc/17038
NSAID API Market: Key Players
Some of the players of NSAID API market include Aurobindo Pharma, Boehringer Ingelheim Group, Cambrex Corporation, Dr. Reddy’s Laboratories, Ltd., BASF SE, Hospira, Inc., Lonza Group, Mylan, Inc., Novartis AG, Pfizer, Inc., Sandoz (Novartis AG), Teva Pharmaceutical Industries Ltd., Actavis Plc, Wuxi Apptec, and Zhejiang NHU Co., Ltd. Currently, these players are focusing on partnering with other companies to acquire a new line of products to add value to their portfolio. Furthermore, companies are also anticipated to focus on expanding their capacities to cater to the vast unmet medical needs of the world.
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Persistence Market Research
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release NSAID API Market Expected to Rise Steadily throughout 2017-2025 here
News-ID: 726734 • Views: 195
More Releases from Persistence Market Research
Ransomware Protection Market is projected to rise to a valuation of around US$ 3 …
Ransomware Protection Market 2022 Ransomware attacks have touched a new high in the 21st century and affected governments, corporates, and even the average citizen. Few are able to recover from this sustained attack to their confidential data in the event of a hit. Conventional firewalls and anti-virus software has been largely ineffective and only specialized ransomware protection software can offer a shield from this scourge. In a new report titled 'Ransomware Protection
Endodontic Devices Market Is To Be Driven By Healthcare Personnel Being Assisted …
The global Endodontic Devices Market is expected to witness a CAGR of 5% and reach US$ 2.7 Bn by the year 2030. With the way in which healthcare data gets accumulated these days (which could be inclusive of medical IoT solutions, DICOM files, and patient records), ultra-modern platforms like data fabrics are in the offing, so that distributed and structured data could be well-managed. This would be healthcare industry's situation
Eye Health Supplements Sales to Top US$ 4.3 Bn by 2031|Key Players- Pfizer Inc., …
Eye Health Supplements Market 2022-2031 The global Eye Health Supplements Market is expected to reach US$ 4.3 Bn by the year 2031 at a CAGR of 6.5%. Healthcare systems have been emphasizing affordability as well as the quality of medical services. However, now, digitization has come through, which would drive a revolution in the same healthcare vertical. 3D bioprinting technology is one such innovation, which is bound to simplify medications. This
Process Modularization To Drive The Wool Market
A new wool market research report published by the Persistence Market Research (PMR) about the global wool market during 2014-2018 and forecast for 2019-2029 provides important insights about the dynamics, trends, volume, and value. According to the study, in 2018, the value of global wool market was approximately US$ 33.8 Bn. This value is expected to grow over the forecast period (2019-2029) to reach nearly US$ 49 Bn by 2029-end. To
More Releases for API
Terminating Twitter API Integrations
Thexyz Inc, the leading private email service that protects people and their data announces that a Twitter authentication apps developed by Thexyz will be discontinued and no longer supported. Thexyz focuses on security, privacy, freedom, and an open internet that respects the rights of individuals. It is a goal to work with organizations that share these values and discontinue support for services that do not. Thexyz has developed applications
Tagraxofusp - API Insight, 2018
Tagraxofusp, sold under the brand name of Elzonris, is an Interleukin 3 (IL-3) conjugated truncated diphtheria toxin. It is composed of catalytic and translocation domains of diphtheria toxin fused via Met-His linker to a full-length human IL-3. Download the sample report @ https://www.pharmaproff.com/request-sample/1168 Tagraxofusp was developed by Stemline Therapeutics Inc. and was approved in December 2018, as the first therapy for blastic plasmacytoid dendritic cell neoplasm. This drug achieved approval after
Cabozantinib- API Insight, 2018
Cabozantinib, sold under the brand name of Cabometyx and Cometriq, is used for the treatment of medullary thyroid cancer and a second line treatment for renal cell carcinoma. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET. Download the sample report @ https://www.pharmaproff.com/request-sample/1164 Discovered and developed by Exelixis Inc., its side-effects include increased liver enzymes, diarrhea, low calcium, mouth sores, decreased
Tyk API Management v2.3
After months working-out in the gym, the new version of Tyk is ready to flex its muscles. Tyk v2.3 is twice as fast, leaner, more extendable and is still available for FREE! London, United Kingdom 8th December, 2016. Tyk Technologies is pleased to announce the v2.3 release of Tyk, the popular open-source API Management platform. Tyk v2.3 builds upon the success of previous releases. The feedback and contributions from Tyk’s thriving open source community, as well as enterprise clients, drove
Telecom API Helps Application Developers to Integrate Various API Services
Telecom API market represents an overall Application Programming Interface (API) services provided by telecom carriers, service providers and aggregators to application developers in order to create mobile applications. Telecom API helps application developers to integrate various services such as payment, voice, SMS and WebRTC into their mobile application. This helps application developers to enhance their customer experience and market their mobile applications among end-users. Telecom API provides many benefits to
Biotech API Surging Worldwide
According to a new research report by RNCOS, entitled “Global Biotech API Market Analysis”, geographies across the world are showing insurgent growth in the biotech API Industry. The US occupied more than half of the share in the global market in 2011, and is the largest producer of biotech APIs. Western European countries occupy around 15% share globally among which, the UK is the largest producer of biotechnology-based APIs. The